Agios Pharmaceuticals (AGIO) Revenue (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 14 years of Revenue data on file, last reported at $44.7 million in Q2 2026.

• Quarterly Revenue rose 259.25% year-over-year to $44.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $98.3 million (up 140.58% YoY) and the FY2025 annual result came in at $54.0 million, up 48.03% from the prior year.
• Revenue rose to $44.7 million in Q2 2026, from $20.7 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $44.7 million in Q2 2026 to a low of $832000.0 in Q1 2022.
• A 5-year average of $10.9 million and a median of $8.4 million in 2024 frame the typical range for Revenue.
• Annual changes were most pronounced in 2023 — Revenue jumped 574.16% — and 2025, when it advanced 6.56%.
• Tracing AGIO's Revenue over 5 years: stood at $4.3 million in 2022, then soared by 64.8% to $7.1 million in 2023, then surged by 51.06% to $10.7 million in 2024, then jumped by 86.09% to $20.0 million in 2025, then soared by 124.09% to $44.7 million in 2026.
• The last three Revenue figures came in at $44.7 million (Q2 2026), $20.7 million (Q1 2026), and $20.0 million (Q4 2025), per Business Quant data.